Evidence map›Paper›PMID 17935553›Full record

Trial reportInternational journal of clinical practice2007

The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.

M Thoenes, A Oguchi, S Nagamia, C S Vaccari, R Hammoud, G E Umpierrez, B V Khan

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International journal of clinical practice, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01683656 (ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART), which is not on this map. Cited by 36 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 4 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01683656 phase4terminatedstarted 2012, after this paper: background citation

ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART

Ran2012Enrolled4Registered outcomes5Posted comparisons0ConditionsAtherosclerosis, HIVArmsNiacin/laropiprant, Placebo
PMID 19095140PMID 19031552PMID 19602880PMID 17302378PMID 19415282PMID 12014436PMID 19275490PMID 12486414PMID 15843671PMID 16137695PMID 16878047PMID 19425222other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 112 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Niacin for primary and secondary prevention of cardiovascular events.The Cochrane database of systematic reviews · 2017 · on this map
    Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Ocular Effects of Niacin: A Review of the Literature.Medical hypothesis, discovery & innovation ophthalmology journal · 2015
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

M ThoenesInstitut für klinische Pharmakologie, Technische Universität Dresden, Dresden, Germany.
A Oguchi
S Nagamia
C S Vaccari
R Hammoud
G E Umpierrez
B V Khan
Emory University · USTU Dresden · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNiacin is an agent that significantly increases high-density lipoprotein cholesterol (HDL-C), but its effects on surrogate markers of atherosclerosis and inflammatory markers are less clear. We studied the effects of niacin on carotid intimal media thickness (IMT), brachial artery reactivity as well as markers of inflammation and the metabolic profile of patients with metabolic syndrome. METHODS AND

resultsFifty patients with the metabolic syndrome (Adult Treatment Panel (ATP) III criteria) were randomised to either extended-release niacin (1000 mg/day) or placebo. After 52 weeks of treatment, there was a change of carotid IMT of +0.009 +/- 0.003 mm in the placebo group and -0.005 +/- 0.002 mm in the niacin group (p = 0.021 between groups). Endothelial function improved by 22% in the group treated with niacin (p < 0.001), whereas no significant changes were seen in the placebo group. High sensitivity C-reactive protein decreased by 20% in the group treated with niacin for 52 weeks (p = 0.013). Niacin increased HDL-C (p < 0.001) and decreased low-density lipoprotein cholesterol and triglycerides (p < 0.001) significantly, and there were no adverse effects on fasting glucose levels after 52 weeks of treatment.

conclusionExtended-release niacin therapy effects a regression in carotid intimal medial thickness and improvement in metabolic parameters (increased HDL and reduced triglycerides). Furthermore, extended-release niacin may demonstrate an anti-atherogenic effect in the metabolic syndrome by improving endothelial function and decreasing vascular inflammation.

Indexed as

AdultAtherosclerosisBiomarkersBlood GlucoseCarotid ArteriesCholesterol, HDLDelayed-Action PreparationsDouble-Blind MethodEndotheliumFemaleHumansHypolipidemic AgentsInflammationMaleMetabolic DiseasesMiddle AgedBiomarkersBlood GlucoseCholesterol, HDLDelayed-Action PreparationsHypolipidemic AgentsNiacin

Identifiers

PMID17935553
OpenAlexW2098566970

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.